Biomedical subjects
D Borchers
Publications and source records attributed to D Borchers.
Stroke in an infant prior to the development of manifestations of neurofibromatosis.
Although the association of strokes and von Recklinghausen neurofibromatosis (NF-1) in young children is uncommon, it is obviously an important complication of this disorder. The few cases that have been described were reported primarily in the radiological literature. Moreover, most of the children reported were already known to have NF-1 or they had a positive family history for it. We report an infant who, at 7 weeks of age, suffered a stroke with resulting hemiparesis, prior to the development of other manifestations of NF-1. Pediatricians and neurologists need to be aware of this association and of the need for careful follow-up of infants with strokes, with particular attention to signs of neurofibromatosis.
[CT analysis of facial skull fracture].
Computer tomography of the facial bones provides the maxillo-facial surgeon with valuable information regarding the type and extent of typical mid-facial fractures (le Fort fractures I to III, fractures of the malar bone, orbital fractures, fractures of the skull base close to the facial bones). The procedure takes little extra time. The patient is saved additional investigations, requiring changes in position which may, at times, be hazardous. Our experience extends to 59 examinations, which is used for an analysis of mid-facial fractures. Some typical examples are given.
[The modification of fracture healing by the cytostatic agent cyclophosphamide - an experimental interdisciplinary study].
The influence of the cytotoxic agent cyclophosphamide (Endoxan) on the course of fracture healing has been investigated in rats. -- In 200 rats the right femur was osteotomized and stabilized by intramedullar nailing. The rats were distributed to 4 groups (n = 50) and submitted to the following scheme of treatment: group I had no further treatment after operation, group II was injected intraperitoneally daily for 14 days with 10 mg cyclophosphamide per kg body-weight beginning at the 3rd day after operation, group III was treated the same dose as group II but until 2 days before operation, group IV was injected the same dose as group II but beginning 20 days after operation. Beside continuous check of body weight and white blood cells as well as x-ray of the hind-limbs, 10, 20, 30, 50 and 70 days after operation both femora were excised and investigated by means of radiologic, scintigraphic, biomechanic as well as histomorphologic methods. The results obtained indicate that cyclophosphamide significantly retards the course of fracture reparation. The degree of retardation was directly depended on the phase of fracture healing process during cyclophosphamide treatment. The retarding effect was supreme in case of coincidence of the beginning of fracture healing and cytotoxic treatment (group II) and diminished relatively in case of cyclophosphamide treatment before (group III) or after (group IV) operation.